Recursion Pharmaceuticals Statistics
Total Valuation
RXRX has a market cap or net worth of $1.76 billion. The enterprise value is $1.18 billion.
Important Dates
The last earnings date was Wednesday, May 6, 2026, before market open.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RXRX has 530.76 million shares outstanding. The number of shares has increased by 51.66% in one year.
| Current Share Class | 524.68M |
| Shares Outstanding | 530.76M |
| Shares Change (YoY) | +51.66% |
| Shares Change (QoQ) | +0.49% |
| Owned by Insiders (%) | 3.04% |
| Owned by Institutions (%) | 63.45% |
| Float | 513.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.53 |
| Forward PS | 19.51 |
| PB Ratio | 1.72 |
| P/TBV Ratio | 3.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.47, with a Debt / Equity ratio of 0.07.
| Current Ratio | 5.47 |
| Quick Ratio | 5.15 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -354.28 |
Financial Efficiency
Return on equity (ROE) is -57.16% and return on invested capital (ROIC) is -34.44%.
| Return on Equity (ROE) | -57.16% |
| Return on Assets (ROA) | -27.66% |
| Return on Invested Capital (ROIC) | -34.44% |
| Return on Capital Employed (ROCE) | -48.38% |
| Weighted Average Cost of Capital (WACC) | 9.68% |
| Revenue Per Employee | $110,680 |
| Profits Per Employee | -$932,960 |
| Employee Count | 600 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.58M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.76% in the last 52 weeks. The beta is 1.05, so RXRX's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | -20.76% |
| 50-Day Moving Average | 3.39 |
| 200-Day Moving Average | 4.46 |
| Relative Strength Index (RSI) | 46.24 |
| Average Volume (20 Days) | 11,882,838 |
Short Selling Information
The latest short interest is 174.40 million, so 32.86% of the outstanding shares have been sold short.
| Short Interest | 174.40M |
| Short Previous Month | 173.93M |
| Short % of Shares Out | 32.86% |
| Short % of Float | 33.94% |
| Short Ratio (days to cover) | 14.00 |
Income Statement
In the last 12 months, RXRX had revenue of $66.41 million and -$559.78 million in losses. Loss per share was -$1.17.
| Revenue | 66.41M |
| Gross Profit | -428.74M |
| Operating Income | -585.27M |
| Pretax Income | -564.36M |
| Net Income | -559.78M |
| EBITDA | -501.23M |
| EBIT | -585.27M |
| Loss Per Share | -$1.17 |
Full Income StatementBalance Sheet
The company has $654.47 million in cash and $72.38 million in debt, with a net cash position of $582.10 million or $1.10 per share.
| Cash & Cash Equivalents | 654.47M |
| Total Debt | 72.38M |
| Net Cash | 582.10M |
| Net Cash Per Share | $1.10 |
| Equity (Book Value) | 1.02B |
| Book Value Per Share | 1.93 |
| Working Capital | 579.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$320.95 million and capital expenditures -$4.90 million, giving a free cash flow of -$325.85 million.
| Operating Cash Flow | -320.95M |
| Capital Expenditures | -4.90M |
| Depreciation & Amortization | 84.04M |
| Net Borrowing | -8.59M |
| Free Cash Flow | -325.85M |
| FCF Per Share | -$0.61 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -881.32% |
| Pretax Margin | -849.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -51.66% |
| Shareholder Yield | -51.66% |
| Earnings Yield | -31.77% |
| FCF Yield | -18.49% |
Analyst Forecast
The average price target for RXRX is $8.00, which is 140.96% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.00 |
| Price Target Difference | 140.96% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RXRX has an Altman Z-Score of 0.98 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.98 |
| Piotroski F-Score | 3 |
